Shenyang Pharmaceutical University, Shenyang, China.
J Food Sci. 2021 Jun;86(6):2753-2765. doi: 10.1111/1750-3841.15731. Epub 2021 Apr 29.
25-Hydroxylprotopanaxadiol-3β, 12β, 20-triol (25-OH-PPD or AD-2) belongs to dammarane ginsenoside, and is commonly obtained from the acidic hydrolysate of total ginsensides of Panax ginseng. This study investigated the potential mechanism of AD-2 toward improving thioacetamide (TAA)-induced hepatic fibrosis in mice. Mice were divided into seven groups: control group, TAA model group, TAA + AD-2 (5, 10, and 20 mg/kg) groups, TAA + silymarin (100 mg/kg) group, and TAA + Fu Fang Biejia (FFBj; 300 mg/kg) group. All mice were treated to intraperitoneal TAA injection to establish a hepatic fibrosis model, and drugs were administered orally. The mechanism and related pathways underlying the AD-2-mediated action against hepatic fibrosis were explored by Western blotting and immunohistochemical staining. After AD-2 treatment, the expression levels of Lipin-1, SREBP1, and F4/80 significantly decreased, meanwhile the protein expressions levels of IL1β, IL1R1, IL18, Bax, Bid, Bcl-2, and cFlips also decreased. Furthermore, AD-2 inhibited RAF and MEK pathways. The results demonstrate that AD-2 can alleviate hepatic fibrosis. The mechanism is likely related to the regulation of lipid accumulation, inflammatory response, apoptosis pathway, and Raf-MEK signaling pathways, which provide a basis for clinical research for the treatment of hepatic fibrosis. PRACTICAL APPLICATION: Ginsenoside is one of the main active ingredients of ginseng, and can alleviate the symptoms of various diseases, for example, hepatic fibrosis. This paper mainly used Western blotting to explore its possible mechanism of action. The goal was to provide a reference for the development of traditional Chinese medicines for hepatic fibrosis.
25-羟基原人参二醇-3β,12β,20-三醇(25-OH-PPD 或 AD-2)属于达玛烷型人参皂苷,通常从人参总皂苷的酸性水解产物中获得。本研究探讨了 AD-2 改善硫代乙酰胺(TAA)诱导的小鼠肝纤维化的潜在机制。将小鼠分为七组:对照组、TAA 模型组、TAA+AD-2(5、10 和 20mg/kg)组、TAA+水飞蓟素(100mg/kg)组和 TAA+复方鳖甲软肝片(FFBj;300mg/kg)组。所有小鼠均经腹腔注射 TAA 建立肝纤维化模型,并进行口服给药。通过 Western 印迹和免疫组化染色探索 AD-2 介导抗肝纤维化作用的机制和相关途径。经 AD-2 处理后,Lipin-1、SREBP1 和 F4/80 的表达水平显著降低,同时 IL1β、IL1R1、IL18、Bax、Bid、Bcl-2 和 cFlips 的蛋白表达水平也降低。此外,AD-2 抑制 RAF 和 MEK 途径。结果表明 AD-2 可减轻肝纤维化。其机制可能与脂质积累、炎症反应、凋亡途径和 Raf-MEK 信号通路的调节有关,为临床研究治疗肝纤维化提供了依据。
人参皂苷是人参的主要活性成分之一,可缓解多种疾病的症状,例如肝纤维化。本文主要采用 Western 印迹法探讨其可能的作用机制,旨在为肝纤维化的中药开发提供参考。